Interferon News and Research

RSS

Newly published manuscripts enhance understanding of the immune system

MedImmune, the global biologics research and development arm of AstraZeneca, today announced that it has achieved a significant scientific milestone by publishing three manuscripts in Nature Immunology that advance the understanding of the immune system and highlight underlying mechanisms in two little-understood disease areas -- chronic obstructive pulmonary disease (COPD) and systemic lupus erythematosus (SLE).

26 Apr 2016

Oxidized mitochondrial nucleoids released from neutrophils may contribute to SLE pathogenesis

Researchers at the Baylor Institute for Immunology Research have discovered that the neutrophils of systemic lupus erythematosus (SLE) patients release oxidized DNA from their mitochondria that can stimulate an unwanted immune response.

19 Apr 2016

Scientists identify human protein that weakens immune response to HIV, other viruses

Scientists at the University of North Carolina School of Medicine and Sanford Burnham Prebys Medical Discovery Institute have identified a human (host) protein that weakens the immune response to HIV and other viruses. The findings, published today in Cell Host & Microbe, have important implications for improving HIV antiviral therapies, creating effective viral vaccines, and advance a new approach to treat cancer.

16 Apr 2016

Patients with genotype 1 chronic HCV infection achieve high SVR rates with VIEKIRAX + EXVIERA

AbbVie, a global biopharmaceutical company, today announced data showing that patients with genotype 1 (GT1) chronic hepatitis C virus (HCV) infection who received the recommended regimen of VIEKIRAX (ombitasvir/paritaprevir/ritonavir tablets) + EXVIERA (dasabuvir tablets), with or without ribavirin (RBV), achieved high sustained virologic response rates at 48 weeks post-treatment (SVR48), regardless of the presence of baseline resistance-associated variants (RAVs).

15 Apr 2016

HLA-C/KIR genotype linked to HBeAg-positive HBV interferon response

The human leucocyte antigen-C and killer immunoglobin-like receptor genotypes are associated with response to interferon-based therapy in patients with chronic hepatitis B virus infection positive for hepatitis B e antigen, say researchers.

13 Apr 2016

Studies offer alternative conclusions on efficacy of DAAs for HIV and HCV co-infected patients

Two separate studies presented today at The International Liver Congress 2016 in Barcelona, Spain have offered alternative conclusions regarding the efficacy of direct-acting antivirals (DAAs) among patients co-infected with HIV and Hepatitis C virus (HCV).

13 Apr 2016

Cell-signaling protein holds key to understanding autoantibody formation in lupus patients

A signaling molecule called interferon gamma could hold the key to understanding how harmful autoantibodies form in lupus patients. The finding could lead to new treatments for the chronic autoimmune disease, said researchers at Penn State College of Medicine.

12 Apr 2016

New biomarker discovery could improve chances of developing effective TB vaccine

A team of scientists led by Oxford University have made a discovery that could improve our chances of developing an effective vaccine against Tuberculosis.

12 Apr 2016

Researchers develop mouse model for testing vaccines, therapeutics to battle Zika virus

A research team at Washington University School of Medicine in St. Louis has established a mouse model for testing of vaccines and therapeutics to battle Zika virus.

6 Apr 2016

UT Southwestern scientists discover mutation that causes X-linked reticulate pigmentary disorder

UT Southwestern Medical Center researchers have discovered a mutation that causes a rare systemic disorder known as X-linked reticulate pigmentary disorder (XLPDR) and, significantly, the unexpected cellular mechanism by which the mutation causes the disease.

29 Mar 2016

Secondary non-Hodgkin's lymphoma a concern for CML patients using TKIs

Patients with chronic myeloid leukaemia who use the tyrosine kinase inhibitor imatinib may be three to four times more likely to develop non-Hodgkin's lymphoma than the general population, study findings indicate.

17 Mar 2016

Real-life data show feasibility of imatinib discontinuation in CML

Italian research shows that long-term imatinib discontinuation is feasible outside of a clinical trial setting for patients with chronic myeloid leukaemia who achieve stable undetectable molecular disease with front-line treatment.

17 Mar 2016

Biomarkers may provide novel approaches to monitoring immunosuppressive therapy in organ transplant patients

Recently discovered biomarkers may provide valuable new approaches to monitoring immunosuppressive drug therapy in organ transplant recipients--with the potential for individualized therapy to reduce organ rejection and minimize side effects, according to a special article in the April issue of Therapeutic Drug Monitoring, official journal of the International Association of Therapeutic Drug Monitoring and Clinical Toxicology.

17 Mar 2016

STING agonists developed to induce cellular death in B cell malignancies

In almost every mammalian cell, you will find the endoplasmic reticulum, a network of continuous membranes responsible for controlling metabolism as well as the folding, assembly and secretion of proteins.

11 Mar 2016

Added benefit of multiple sclerosis drug fingolimod not proven, says IQWiG

Since its approval in 2011, the multiple sclerosis drug fingolimod (Gilenya) has already undergone three early benefit assessments, all of which were mainly based on the approval study TRANSFORMS. After a new modification of the therapeutic indication by the regulatory authorities, the Federal Joint Committee again commissioned the German Institute for Quality and Efficiency in Health Care to examine the added benefit of the drug in accordance with the Act on the Reform of the Market for Medicinal Products.

9 Mar 2016

Metabolic syndrome treatment benefits MS patients

Oral antidiabetic medications have beneficial anti-inflammatory effects in patients with multiple sclerosis and metabolic syndrome, providing support for a link between metabolism and autoimmunity, researchers report.

9 Mar 2016

Omalizumab treatment significantly decreases colds in inner-city children with allergic asthma

Treatment with omalizumab significantly decreases the number of colds in inner-city children with allergic asthma, researchers reported at a press conference today at the American Academy of Allergy, Asthma and Immunology 2016 Annual Meeting in Los Angeles. Omalizumab, sold under the brand name Xolair, is an injectable antibody that can be used to treat asthma cases not controlled by inhaled corticosteroids.

7 Mar 2016

PharmaEssentia to present results of P1101 + ribavirin phase II trial in HCV patients at APASL 2016

PharmaEssentia Corporation announces presentation of the results of the phase II trial for P1101 + ribavirin in patients with chronic HCV genotype 1 infection at the 25th Conference of the Asian Pacific Association for the Study of the Liver, taking place in Tokyo, Japan from February 20 to 24, 2016 (APASL 2016). Data will be presented by the study coordinating investigator Prof. Wan-Long Chuang (Taiwan) at the HCV parallel oral session on Feb 22nd (15:45-17:45).

22 Feb 2016

Discovery could lead to more effective vaccines, personalised therapies for TB

Tuberculosis (TB) used to kill one in seven people around the world before the advent of antibiotics. However the increasing prevalence of multi-drug resistant TB means that doctors are running out of options in trying to combat this bacterium.

18 Feb 2016

Promising phase II results for ozanimod in MS

The selective sphingosine 1-phosphate receptor inhibitor ozanimod significantly reduces lesion activity in patients with relapsing-remitting multiple sclerosis, shows a phase II study published in The Lancet Neurology.

17 Feb 2016

Interferon News and Research

Newly published manuscripts enhance understanding of the immune system

Oxidized mitochondrial nucleoids released from neutrophils may contribute to SLE pathogenesis

Scientists identify human protein that weakens immune response to HIV, other viruses

Patients with genotype 1 chronic HCV infection achieve high SVR rates with VIEKIRAX + EXVIERA

HLA-C/KIR genotype linked to HBeAg-positive HBV interferon response

Studies offer alternative conclusions on efficacy of DAAs for HIV and HCV co-infected patients

Cell-signaling protein holds key to understanding autoantibody formation in lupus patients

New biomarker discovery could improve chances of developing effective TB vaccine

Researchers develop mouse model for testing vaccines, therapeutics to battle Zika virus

UT Southwestern scientists discover mutation that causes X-linked reticulate pigmentary disorder

Secondary non-Hodgkin's lymphoma a concern for CML patients using TKIs

Real-life data show feasibility of imatinib discontinuation in CML

Biomarkers may provide novel approaches to monitoring immunosuppressive therapy in organ transplant patients

STING agonists developed to induce cellular death in B cell malignancies

Added benefit of multiple sclerosis drug fingolimod not proven, says IQWiG

Metabolic syndrome treatment benefits MS patients

Omalizumab treatment significantly decreases colds in inner-city children with allergic asthma

PharmaEssentia to present results of P1101 + ribavirin phase II trial in HCV patients at APASL 2016

Discovery could lead to more effective vaccines, personalised therapies for TB

Promising phase II results for ozanimod in MS

Leveraging the power of automation to boost research

Automating research - solutions and best practices

How can microdialysis benefit drug development

Latest News